SCHEMBL791285

SCHEMBL791285

O=C(Nc1ccccc1)c1cccc(Br)c1OCl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.61
MEN1 O00255 5/20 0.61
USP2 O75604 1/20 0.56
MAPT P10636 1/20 0.56
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
ALDH1A1 P00352 2/20 0.51
METAP2 P50579 1/20 0.51
HPGD P15428 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HSPD1 P10809 1/20 0.49
HSPE1 P61604 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
F2R P25116 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL29276588 0.98 KMT2A (0.60) KMT2AMEN1USP2MAPTNPC1
SCHEMBL3441194 0.86 KMT2A (0.68) KMT2AMEN1USP2MAPTNPC1
SCHEMBL24118812 0.85 NPC1 (0.62) KMT2AMEN1USP2MAPTNPC1
SCHEMBL8469266 0.83 SMO (0.56) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL28388092 0.83 MEN1 (0.65) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL28017780 0.82 SMO (0.55) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL882734 0.80 KMT2A (0.80) KMT2AMEN1USP2MAPTNPC1
SCHEMBL30410198 0.79 PRNP (0.46) KMT2AALDH1A1HPGDKDM4EHSD17B10
SCHEMBL8052698 0.78 KMT2A (0.69) KMT2AMEN1USP2MAPTNPC1
SCHEMBL28158256 0.77 MEN1 (0.60) KMT2AMEN1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY INC (US) 2026-04-02 US claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
WO-2024064209-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY, INC. (US) 2024-03-28 WO claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
WO-2022040799-A1 ANTIMICROBIAL COMPOSITION GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) 2022-03-03 WO claimed
EP-3927334-A1 NONHORMONAL UNISEX CONTRACEPTIVES The Regents of The University of California (US) 2021-12-29 EP claimed
US-20210369652-A1 Nonhormonal Unisex Contraceptives THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-12-02 US claimed
US-11166926-B2 Compositions and methods for protecting a host from enteric toxigenic pathogens THE HOSPITAL FOR SICK CHILDREN (CA) 2021-11-09 US claimed
CN-113453673-A Non-hormone contraceptive for both men and women 加利福尼亚大学董事会 2021-09-28 CN claimed
EP-2222319-A2 TOPICAL DRUGS FOR USE IN ANTIFUNGAL THERAPY Bayer Consumer Care AG (CH) 2010-09-01 EP claimed
WO-2009062746-A2 TOPICAL DRUGS FOR USE IN ANTIFUNGAL THERAPY BAYER CONSUMER CARE AG (CH) 2009-05-22 WO claimed
US-7198800-B1 Compositions and methods Ko, Thomas Sai Ying (CN) 2007-04-03 US claimed
EP-1696855-A1 DERMAL DRUG DELIVERY SYSTEM Medpharm Limited (GB) 2006-09-06 EP claimed
US-20060130266-A1 Dermal drug delivery system MEDPHARM LIMITED (GB) 2006-06-22 US claimed
WO-2005058226-A1 DERMAL DRUG DELIVERY SYSTEM MEDPHARM LIMITED (GB) 2005-06-30 WO claimed
JP-2003514875-A 2003-04-22 JP claimed
EP-1231948-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION Ever Power Holding Inc. (VG) 2002-08-21 EP claimed
WO-2001037890-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION EVER POWER HOLDING INC (VG) 2001-05-31 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS AHCY, MACO1, ME3 KMT2A 3975/4885MEN1 2966/4885USP2 2990/4885
US-20210369652-A1 Nonhormonal Unisex Contraceptives UQCRC1, UQCRC2, MCU KMT2A 4070/4885MEN1 2175/4885USP2 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.